Literature DB >> 26528660

Recommended treatment strategies for patients with excessive daytime sleepiness.

Russell P Rosenberg1.   

Abstract

Excessive daytime sleepiness (EDS) is a common and bothersome phenomenon. It can be associated with insufficient sleep syndrome, narcolepsy, idiopathic hypersomnia, obstructive sleep apnea, shift work disorder, Kleine-Levin syndrome, or Parkinson's disease. Once the underlying cause of the excessive sleepiness is determined, clinicians must select the most appropriate behavioral and pharmacologic interventions to reduce daytime sleepiness, alleviate other symptoms, improve functioning, and ensure the safety of patients and those around them. Patient history, adverse effects, and efficacy in specific conditions should be considered in pharmacologic treatment options for patients with EDS. © Copyright 2015 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Year:  2015        PMID: 26528660     DOI: 10.4088/JCP.14019tx3c

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  4 in total

1.  Natural Cannabinoids as Templates for Sleep Disturbances Treatments.

Authors:  Eric Murillo-Rodríguez; Sérgio Machado; Claudio Imperatori; Tetsuya Yamamoto; Henning Budde
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Capacity of the Edmonton Symptom Assessment System and the Canadian Problem Checklist to screen clinical insomnia in cancer patients.

Authors:  Josée Savard; Hans Ivers; Marie-Hélène Savard
Journal:  Support Care Cancer       Date:  2016-05-18       Impact factor: 3.603

3.  Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea.

Authors:  Atul Malhotra; Colin Shapiro; Jean-Louis Pepin; Jan Hedner; Mansoor Ahmed; Nancy Foldvary-Schaefer; Patrick J Strollo; Geert Mayer; Kathleen Sarmiento; Michelle Baladi; Patricia Chandler; Lawrence Lee; Richard Schwab
Journal:  Sleep       Date:  2020-02-13       Impact factor: 5.849

4.  A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor.

Authors:  Lawrence P Carter; Jack E Henningfield; Y Grace Wang; Yuan Lu; Debra Kelsh; Bradley Vince; Edward Sellers
Journal:  J Psychopharmacol       Date:  2018-10-01       Impact factor: 4.153

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.